They lowered the standards to use the Mrna

This is interesting as the clinical batches did not meet the standards of the commercial batches. What this means is that the mRNA should be around 75% but in the commercial batches, it dropped down to fifty percent. So the regulators changed the standard to get it out. This means that the proteins fractionated and they did not have a clue what they would do as the trials have never been done. So logically if the batches had any problems with regard to the temperature or the time left idle before use the degradation would be higher. Perhaps this is why the rollouts had patchy results.nd what would they do in the long term? So How does one think about having a bit of fractionated DNA floating around in the bloodstream, unprotected by the lipid membrane.? Bit Technical but you get the drift. www.bitchute.com...

Youtube LINK